Cargando…

Molecular Mechanisms Provide a Landscape for Biomarker Selection for Schizophrenia and Schizoaffective Psychosis

Research evaluating the role of the 5,10-methylenetetrahydrofolate reductase (MTHFR C677T) gene in schizophrenia has not yet provided an extended understanding of the proximal pathways contributing to the 5-10-methylenetetrahydrofolate reductase (MTHFR) enzyme’s activity and the distal pathways bein...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fryar-Williams, Stephanie, Strobel, Jörg, Clements, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10607016/ https://www.ncbi.nlm.nih.gov/pubmed/37894974 http://dx.doi.org/10.3390/ijms242015296

Ejemplares similares

Molecular Mechanism Biomarkers Predict Diagnosis in Schizophrenia and Schizoaffective Psychosis, with Implications for Treatment
por: Fryar-Williams, Stephanie, et al.
Publicado: (2023)

Biomarkers of a five-domain translational substrate for schizophrenia and schizoaffective psychosis
por: Fryar-Williams, Stephanie, et al.
Publicado: (2015)

Fundamental Role of Methylenetetrahydrofolate Reductase 677 C → T Genotype and Flavin Compounds in Biochemical Phenotypes for Schizophrenia and Schizoaffective Psychosis
por: Fryar-Williams, Stephanie
Publicado: (2016)

Biomarker Case-Detection and Prediction with Potential for Functional Psychosis Screening: Development and Validation of a Model Related to Biochemistry, Sensory Neural Timing and End Organ Performance
por: Fryar-Williams, Stephanie, et al.
Publicado: (2016)

Carbamazepine and psychotherapy in the treatment of schizoaffective psychosis.
por: Cegalis, J. A., et al.
Publicado: (1985)

Structured lifestyle education for people with schizophrenia, schizoaffective disorder and first-episode psychosis (STEPWISE): randomised controlled trial
por: Holt, Richard I. G., et al.
Publicado: (2019)

Neurophysiological Distinction between Schizophrenia and Schizoaffective Disorder
por: Mathalon, Daniel H., et al.
Publicado: (2010)

Alcohol Use Disorder and Schizophrenia or Schizoaffective Disorder
por: Archibald, Luke, et al.
Publicado: (2019)

Liraglutide and the management of overweight and obesity in people with schizophrenia, schizoaffective disorder and first-episode psychosis: protocol for a pilot trial
por: Whicher, Clare Alexandra, et al.
Publicado: (2019)

Efficacy and tolerability of Aripiprazole in Patients with Schizophrenia & Schizoaffective Disorders
por: Andrade, Chittaranjan
Publicado: (2004)

Efficacy and Tolerability of Aripiprazole in Patients with Schizophrenia & Schizoaffective Disorders
por: Chavda, R.K., et al.
Publicado: (2004)

Measuring Emotional Awareness in Patients With Schizophrenia and Schizoaffective Disorders
por: Maaßen, Eva, et al.
Publicado: (2021)

Cardiovascular Risk for Patients With and Without Schizophrenia, Schizoaffective Disorder, or Bipolar Disorder
por: Rossom, Rebecca C., et al.
Publicado: (2022)

5.3 EVIDENCE ON A TRANSDIAGNOSTIC PSYCHOSIS SPECTRUM OF SCHIZOPHRENIA, SCHIZOAFFECTIVE AND PSYCHOTIC BIPOLAR DISORDER IN THE BIPOLAR-SCHIZOPHRENIA NETWORK ON INTERMEDIATE PHENOTYPES (B-SNIP)
por: Reininghaus, Ulrich, et al.
Publicado: (2018)

The continuing story of schizophrenia and schizoaffective disorder: One condition or two?
por: Hartman, Leah I., et al.
Publicado: (2019)

Religious Coping Strategies for Religious Patients with Schizophrenia and Schizoaffective Disorder
por: Gedevani, E., et al.
Publicado: (2022)

The use of technologies and social media in patients with schizophrenia and schizoaffective disorder
por: Elleuch, O., et al.
Publicado: (2022)

Clinical factors affecting functioning in patients with schizophrenia or schizoaffective disorder
por: Neily, C., et al.
Publicado: (2022)

Reducing weight gain in people with schizophrenia, schizoaffective disorder, and first episode psychosis: describing the process of developing the STructured lifestyle Education for People With SchizophrEnia (STEPWISE) intervention
por: Carey, Marian E., et al.
Publicado: (2018)

microRNA expression in the prefrontal cortex of individuals with schizophrenia and schizoaffective disorder
por: Perkins, Diana O, et al.
Publicado: (2007)

Social function in schizophrenia and schizoaffective disorder: Associations with personality, symptoms and neurocognition
por: Lysaker, Paul H, et al.
Publicado: (2004)

Trauma and Posttraumatic Stress Disorder (PTSD) in Patients with Schizophrenia or Schizoaffective Disorder
por: Lommen, Miriam J. J., et al.
Publicado: (2009)

Blonanserin-induced Mood Alteration in Schizophrenia and Schizoaffective Disorder: Two Cases
por: Min, Aran, et al.
Publicado: (2013)

Distinctive transcriptome alterations of prefrontal pyramidal neurons in schizophrenia and schizoaffective disorder
por: Arion, Dominique, et al.
Publicado: (2015)

The Effectiveness of Cross-Tapering Switching to Ziprasidone in Patients with Schizophrenia or Schizoaffective Disorder
por: Ko, Young-Hoon, et al.
Publicado: (2014)

Evidence for Distinguishable Treatment Costs among Paranoid Schizophrenia and Schizoaffective Disorder
por: Hirjak, Dusan, et al.
Publicado: (2016)

Brain structural changes in schizoaffective disorder compared to schizophrenia and bipolar disorder
por: Amann, B. L., et al.
Publicado: (2015)

Study of the Effect of Memantine on Negative Sign in Patients with Schizophrenia and Schizoaffective Disorders
por: Tavakoli-Ardakani, Maria, et al.
Publicado: (2018)

Impairment in delay discounting in schizophrenia and schizoaffective disorder but not primary mood disorders
por: Brown, Hannah E., et al.
Publicado: (2018)

Risk of readmission in patients with schizophrenia and schizoaffective disorder newly prescribed clozapine
por: Kesserwani, Jad, et al.
Publicado: (2019)

Social and Neurocognitive Deficits in Remitted Patients with Schizophrenia, Schizoaffective and Bipolar Disorder
por: Dehelean, Liana, et al.
Publicado: (2021)

Hummingbird Study: Results from an Exploratory Trial Assessing the Performance and Acceptance of a Digital Medicine System in Adults with Schizophrenia, Schizoaffective Disorder, or First-Episode Psychosis
por: Fowler, J Corey, et al.
Publicado: (2021)

Testing the hypothesis of subtypes of nonadherence in schizophrenia and schizoaffective disorder: A prospective study
por: Vega, Dulcinea, et al.
Publicado: (2020)

Reaction Time and Visual Memory in Connection with Alcohol Use in Schizophrenia and Schizoaffective Disorder
por: Mazumder, Atiqul Haq, et al.
Publicado: (2021)

The recovery of homicidal people diagnosed with schizophrenia and schizoaffective disorder—An interpretative phenomenological analysis
por: Kovács, Asztrik, et al.
Publicado: (2023)

Risk Factors, Clinical Features, and Polygenic Risk Scores in Schizophrenia and Schizoaffective Disorder Depressive-Type
por: Dennison, Charlotte A, et al.
Publicado: (2021)

Impact of race on efficacy and safety during treatment with olanzapine in schizophrenia, schizophreniform or schizoaffective disorder
por: Stauffer, Virginia L, et al.
Publicado: (2010)

Criteria for symptom remission revisited: a study of patients affected by schizophrenia and schizoaffective disorders
por: Pinna, Federica, et al.
Publicado: (2013)

Using blood cytokine measures to define high inflammatory biotype of schizophrenia and schizoaffective disorder
por: Boerrigter, Danny, et al.
Publicado: (2017)

PM395. The Effectiveness of Cross-Tapering Switching to Ziprasidone in Patients with Schizophrenia or Schizoaffective Disorder
por: Na, Kyoungsae, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_krhlrb7shvq2v5ajj99o6bqonc